Why the study?
A better mechanistic understanding of age-dependent processes defining anthracycline cardiotoxicity is needed given increasing survival, more elderly cancer patients, and particular susceptibility at extremes of age.
How does age affect the underlying molecular pathways of anthracycline-associated cardiotoxicity?
How does age affect the underlying molecular pathways of anthracycline-associated cardiotoxicity?
Understanding age-dependent molecular pathways is crucial for developing preventive strategies against anthracycline-induced cardiotoxicity in both pediatric and elderly cancer patients.
Cardio-Oncology has blossomed as a new field in cardiovascular medicine, in large part due to new therapies, which may have cardiovascular sequelae. Despite this, anthracyclines still serve as cornerstone therapy for most pediatric cancers, several solid tumors and hematological malignancies. Cardiotoxicity is the main limiting concern with anthracyclines, and this is particularly an issue in patients in extremes of age (both young and old patients). Pediatric hearts are susceptible for cardiotoxicity, while in older patients, concomitant risk factors may contribute to lower threshold for cardiotoxic effects. With increasing patient survival, a significant increase in elderly cancer patients and long-term cardiotoxicity effects of anthracyclines, a better mechanistic understanding of age-dependent processes-that define cardiotoxicity-is needed. This review sheds light on how age affects underlying molecular pathways of anthracycline-associated cardiotoxicity and aims to provide preventive strategies that can be used in clinical practice.
No takes yet. Share an insight, caveat, or question.
Screever et al. (2020) conducted a review in Anthracycline-associated cardiotoxicity. Anthracyclines was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: